BioNTech SE
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which… Read more
BioNTech SE (BNTX) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.046x
Based on the latest financial reports, BioNTech SE (BNTX) has a cash flow conversion efficiency ratio of 0.046x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($854.59 Million) by net assets ($18.48 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
BioNTech SE - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how BioNTech SE's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
BioNTech SE Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of BioNTech SE ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Skechers USA Inc
NYSE:SKX
|
0.103x |
|
Banca Monte dei Paschi di Siena S.p.A
PINK:BMDPF
|
0.018x |
|
Hyundai Rotem Co
KO:064350
|
-0.010x |
|
Chroma ATE Inc
TW:2360
|
0.032x |
|
CERIDIAN HCM HLDG
F:CQL
|
N/A |
|
Samsung Fire And Marine Ins Pref
KO:000815
|
0.068x |
|
EDP - Energias de Portugal S.A
OTCGREY:ELCPF
|
0.051x |
|
Fresenius Medical Care AG & Co. KGaA
PINK:FMCQF
|
0.053x |
Annual Cash Flow Conversion Efficiency for BioNTech SE (2017–2024)
The table below shows the annual cash flow conversion efficiency of BioNTech SE from 2017 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $19.41 Billion | $207.70 Million | 0.011x | -95.97% |
| 2023-12-31 | $20.25 Billion | $5.37 Billion | 0.265x | -60.81% |
| 2022-12-31 | $20.06 Billion | $13.58 Billion | 0.677x | +805.01% |
| 2021-12-31 | $11.89 Billion | $889.70 Million | 0.075x | +860.12% |
| 2020-12-31 | $1.37 Billion | $-13.50 Million | -0.010x | +97.55% |
| 2019-12-31 | $493.49 Million | $-198.50 Million | -0.402x | -84.59% |
| 2018-12-31 | $267.00 Million | $-58.18 Million | -0.218x | -119.98% |
| 2017-12-31 | $-48.21 Million | $-52.56 Million | 1.090x | -- |